Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 5th edition, 486 pages

Free download

  Colorectal Neoplasms

  Free Subscription

Articles published in J Clin Oncol

Retrieve available abstracts of 43 articles:
HTML format

Single Articles

    September 2020
  1. MLECNIK B, Bifulco C, Bindea G, Marliot F, et al
    Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.
    J Clin Oncol. 2020 Sep 8:JCO1903205. doi: 10.1200/JCO.19.03205.
    PubMed     Abstract available

    August 2020
  2. CREMOLINI C, Antoniotti C, Stein A, Bendell J, et al
    Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer.
    J Clin Oncol. 2020 Aug 20:JCO2001225. doi: 10.1200/JCO.20.01225.
    PubMed     Abstract available

    April 2020
  3. FUKUOKA S, Hara H, Takahashi N, Kojima T, et al
    Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
    J Clin Oncol. 2020 Apr 28:JCO1903296. doi: 10.1200/JCO.19.03296.
    PubMed     Abstract available

    March 2020
  4. DELATTRE JF, Cohen R, Henriques J, Falcoz A, et al
    Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR).
    J Clin Oncol. 2020 Mar 13:JCO1901960. doi: 10.1200/JCO.19.01960.
    PubMed     Abstract available

    January 2020
  5. BROWN LC, Armstrong AJ
    Has Mismatch Repair-Deficient Cancer Met Its MATCH?
    J Clin Oncol. 2020;38:183-187.

  6. AZAD NS, Gray RJ, Overman MJ, Schoenfeld JD, et al
    Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study.
    J Clin Oncol. 2020;38:214-222.
    PubMed     Abstract available

    November 2019
  7. LE DT, Kim TW, Van Cutsem E, Geva R, et al
    Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.
    J Clin Oncol. 2019 Nov 14:JCO1902107. doi: 10.1200/JCO.19.02107.
    PubMed     Abstract available

    October 2019
  8. MODEST DP, Martens UM, Riera-Knorrenschild J, Greeve J, et al
    FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).
    J Clin Oncol. 2019 Oct 14:JCO1901340. doi: 10.1200/JCO.19.01340.
    PubMed     Abstract available

    September 2019
  9. SUNDAR R, Tan IBH, Chee CE
    Negative Predictive Biomarkers in Colorectal Cancer: PRESSING Ahead.
    J Clin Oncol. 2019 Sep 24:JCO1901977. doi: 10.1200/JCO.19.01977.

  10. MORANO F, Corallo S, Lonardi S, Raimondi A, et al
    Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.
    J Clin Oncol. 2019 Sep 20:JCO1901254. doi: 10.1200/JCO.19.01254.
    PubMed     Abstract available

    August 2019
  11. GUERCIO BJ, Zhang S, Ou FS, Venook AP, et al
    Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
    J Clin Oncol. 2019 Aug 13:JCO1901019. doi: 10.1200/JCO.19.01019.
    PubMed     Abstract available

    June 2019
  12. UENO H, Ishiguro M, Nakatani E, Ishikawa T, et al
    Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial.
    J Clin Oncol. 2019 Jun 10:JCO1802059. doi: 10.1200/JCO.18.02059.
    PubMed     Abstract available

  13. STEBBING J, Singh Wasan H
    Decoding Metastatic Colorectal Cancer to Improve Clinical Decision Making.
    J Clin Oncol. 2019 Jun 7:JCO1901185. doi: 10.1200/JCO.19.01185.

    May 2019
  14. SMITH TG, Troeschel AN, Castro KM, Arora NK, et al
    Perceptions of Patients With Breast and Colon Cancer of the Management of Cancer-Related Pain, Fatigue, and Emotional Distress in Community Oncology.
    J Clin Oncol. 2019 May 17:JCO1801579. doi: 10.1200/JCO.18.01579.
    PubMed     Abstract available

  15. LENZ HJ, Ou FS, Venook AP, Hochster HS, et al
    Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
    J Clin Oncol. 2019 May 1:JCO1802258. doi: 10.1200/JCO.18.02258.
    PubMed     Abstract available

    April 2019
  16. SALZ T, Lavery JA, Lipitz-Snyderman AN, Boudreau DM, et al
    Trends in Opioid Use Among Older Survivors of Colorectal, Lung, and Breast Cancers.
    J Clin Oncol. 2019;37:1001-1011.
    PubMed     Abstract available

  17. LIEU C, Kennedy EB, Bergsland E, Berlin J, et al
    Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline.
    J Clin Oncol. 2019 Apr 15:JCO1900281. doi: 10.1200/JCO.19.00281.
    PubMed     Abstract available

    March 2019
  18. VAN CUTSEM E, Huijberts S, Grothey A, Yaeger R, et al
    Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.
    J Clin Oncol. 2019 Mar 20:JCO1802459. doi: 10.1200/JCO.18.02459.
    PubMed     Abstract available

  19. INNOCENTI F, Ou FS, Qu X, Zemla TJ, et al
    Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.
    J Clin Oncol. 2019 Mar 13:JCO1801798. doi: 10.1200/JCO.18.01798.
    PubMed     Abstract available

  20. SALVADOR MU, Truelson MRF, Mason C, Souders B, et al
    Comprehensive Paired Tumor/Germline Testing for Lynch Syndrome: Bringing Resolution to the Diagnostic Process.
    J Clin Oncol. 2019;37:647-657.
    PubMed     Abstract available

    February 2019
  21. SHUEN AY, Lanni S, Panigrahi GB, Edwards M, et al
    Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue.
    J Clin Oncol. 2019;37:461-470.
    PubMed     Abstract available

  22. ROVITHI M, Gerritse SL, Honeywell RJ, Ten Tije AJ, et al
    Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors.
    J Clin Oncol. 2019;37:411-418.
    PubMed     Abstract available

  23. YURGELUN MB, Kastrinos F
    Tumor Testing for Microsatellite Instability to Identify Lynch Syndrome: New Insights Into an Old Diagnostic Strategy.
    J Clin Oncol. 2019;37:263-265.

  24. LATHAM A, Srinivasan P, Kemel Y, Shia J, et al
    Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.
    J Clin Oncol. 2019;37:286-295.
    PubMed     Abstract available

    January 2019
  25. OGURA A, Konishi T, Cunningham C, Garcia-Aguilar J, et al
    Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer.
    J Clin Oncol. 2019;37:33-43.
    PubMed     Abstract available

    November 2018
  26. MODEST DP, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, et al
    Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
    J Clin Oncol. 2018 Nov 2:JCO1800052. doi: 10.1200/JCO.18.00052.
    PubMed     Abstract available

    October 2018
  27. GUINTER MA, McCullough ML, Gapstur SM, Campbell PT, et al
    Associations of Pre- and Postdiagnosis Diet Quality With Risk of Mortality Among Men and Women With Colorectal Cancer.
    J Clin Oncol. 2018 Oct 19:JCO1800714. doi: 10.1200/JCO.18.00714.
    PubMed     Abstract available

    September 2018
  28. QIN S, Li J, Wang L, Xu J, et al
    Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial.
    J Clin Oncol. 2018 Sep 10:JCO2018783183. doi: 10.1200/JCO.2018.78.3183.
    PubMed     Abstract available

    June 2018
  29. MO M, Yang J, Zhu X, Zhu J, et al
    Bevacizumab Maintenance in Metastatic Colorectal Cancer.
    J Clin Oncol. 2018 Jun 4:JCO2018783795. doi: 10.1200/JCO.2018.78.3795.

    May 2018
  30. VAN DIJK E, Biesma HD, Cordes M, Smeets D, et al
    Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.
    J Clin Oncol. 2018 May 24:JCO2017771782. doi: 10.1200/JCO.2017.77.1782.
    PubMed     Abstract available

    April 2018
    Advances in Adjuvant Therapy for Colon Cancer: P value or Practical Value.
    J Clin Oncol. 2018 Apr 5:JCO2018778423. doi: 10.1200/JCO.2018.77.8423.

  32. ANDRE T, Vernerey D, Mineur L, Bennouna J, et al
    3 Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
    J Clin Oncol. 2018 Apr 5:JCO2017760355. doi: 10.1200/JCO.2017.76.0355.
    PubMed     Abstract available

  33. SOBRERO A, Lonardi S, Rosati G, Di Bartolomeo M, et al
    FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
    J Clin Oncol. 2018 Apr 5:JCO2017762187. doi: 10.1200/JCO.2017.76.2187.
    PubMed     Abstract available

    March 2018
  34. SUN R, Horiguchi M, Wei LJ
    Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival.
    J Clin Oncol. 2018 Mar 20:JCO2017775643. doi: 10.1200/JCO.2017.77.5643.

    February 2018
  35. FADELU T, Zhang S, Niedzwiecki D, Ye X, et al
    Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
    J Clin Oncol. 2018 Feb 28:JCO2017755413. doi: 10.1200/JCO.2017.75.5413.
    PubMed     Abstract available

    January 2018
  36. OVERMAN MJ, Lonardi S, Wong KYM, Lenz HJ, et al
    Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
    J Clin Oncol. 2018 Jan 20:JCO2017769901. doi: 10.1200/JCO.2017.76.9901.
    PubMed     Abstract available

  37. APARICIO T, Ghiringhelli F, Boige V, Le Malicot K, et al
    Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).
    J Clin Oncol. 2018 Jan 18:JCO2017752931. doi: 10.1200/JCO.2017.75.2931.
    PubMed     Abstract available

  38. KENZIK KM, Balentine C, Richman J, Kilgore M, et al
    New-Onset Cardiovascular Morbidity in Older Adults With Stage I to III Colorectal Cancer.
    J Clin Oncol. 2018 Jan 16:JCO2017749739. doi: 10.1200/JCO.2017.74.9739.
    PubMed     Abstract available

    December 2017
  39. BUTOW PN, Turner J, Gilchrist J, Sharpe L, et al
    Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence.
    J Clin Oncol. 2017;35:4066-4077.
    PubMed     Abstract available

  40. XU J, Kim TW, Shen L, Sriuranpong V, et al
    Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.
    J Clin Oncol. 2017 Dec 7:JCO2017743245. doi: 10.1200/JCO.2017.74.3245.
    PubMed     Abstract available

    November 2017
  41. COLON-LOPEZ V, Shiels MS, Machin M, Ortiz AP, et al
    Anal Cancer Risk Among People With HIV Infection in the United States.
    J Clin Oncol. 2017 Nov 15:JCO2017749291. doi: 10.1200/JCO.2017.74.9291.
    PubMed     Abstract available

  42. WHITNEY RL, Bell JF, Tancredi DJ, Romano PS, et al
    Hospitalization Rates and Predictors of Rehospitalization Among Individuals With Advanced Cancer in the Year After Diagnosis.
    J Clin Oncol. 2017;35:3610-3617.
    PubMed     Abstract available

    February 2017
  43. LOBERG M, Holme O, Kalager M
    Aspirin, Colorectal Cancer, and Cause of Death: A Complex Landscape.
    J Clin Oncol. 2017;35:568-569.

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.